BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15806543)

  • 1. Allogeneic graft-versus-hepatoblastoma effect.
    Inaba H; Handgretinger R; Furman W; Hale G; Leung W
    Pediatr Blood Cancer; 2006 Apr; 46(4):501-5. PubMed ID: 15806543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic hematopoetic cell transplantation in patients with solid tumors - Contra].
    Bokemeyer C; Kanz L
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2215. PubMed ID: 12397552
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Tan PL; Wagner JE; Auerbach AD; Defor TE; Slungaard A; Macmillan ML
    Pediatr Blood Cancer; 2006 May; 46(5):630-6. PubMed ID: 16078221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
    Niwa A; Umeda K; Awaya T; Yui Y; Matsubara H; Hiramatsu H; Watanabe K; Adachi S; Itoh T; Uemoto S; Nakahata T
    Pediatr Transplant; 2009 Mar; 13(2):259-62. PubMed ID: 18444949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
    Bishop MR; Fowler DH; Marchigiani D; Castro K; Kasten-Sportes C; Steinberg SM; Gea-Banacloche JC; Dean R; Chow CK; Carter C; Read EJ; Leitman S; Gress R
    J Clin Oncol; 2004 Oct; 22(19):3886-92. PubMed ID: 15314059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-lymphoma effect after reduced intensity allogeneic hematopoietic stem cell transplantation from HLA-two loci mismatched father in a patient with refractory non-Hodgkin lymphoma.
    Suminoe A; Matsuzaki A; Koga Y; Hatano M; Hara T; Hara T
    Turk J Pediatr; 2009; 51(5):500-3. PubMed ID: 20112609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer.
    Arya M; Chao D; Patel HR
    Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.